Episode 57: 23andMe

This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes.

From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine.

We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized?

This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech.

#23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

For most of human history, understanding your family story meant opening old photo albums, calling relatives, digging through records, and hoping somebody remembered enough names to build a family tree.

Then one company came along and said: Forget the paperwork. Spit into a tube.

Suddenly, people were discovering unknown relatives, uncovering ethnic backgrounds they never knew existed, and asking questions that were once reserved for genetic counselors and medical researchers.

This is the story of 23andMe.

A company that didn't begin with a new drug, a groundbreaking therapy, or a revolutionary medical device. Instead, it began with a deceptively simple question: What if everyone could access their own genome?

But here's what makes this story fascinating. 23andMe wasn't really selling DNA tests. They were selling identity. And in the process, they quietly assembled one of the largest human genetic databases on Earth.

That database would attract pharmaceutical giants, create billion-dollar partnerships, trigger major privacy debates, survive regulatory battles, ride the SPAC wave, and eventually become one of the most dramatic stories in modern biotech.

Because 23andMe didn't just ask people where they came from. They asked a much larger question: Who owns your biology?

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

Establishment: Anne Wojcicki and the Silicon Valley DNA Experiment

Let's go back to 2006.

Consumer genetics barely existed. DNA sequencing still felt expensive and largely academic. Most people had never heard terms like SNPs, haplotypes, or genome-wide association studies. Genetic testing lived mostly inside hospitals and research laboratories.

Then came Anne Wojcicki.

Wojcicki wasn't a geneticist by training. She worked as a healthcare investment analyst and spent years observing the pharmaceutical industry from a financial perspective. During that time, she noticed a recurring problem: medicine was largely focused on reacting after patients became sick rather than predicting disease before it happened.

Genetics looked like a missing piece of that puzzle.

She partnered with co-founders Linda Avey and Paul Cusenza, and together they developed an idea that sounded almost unrealistic at the time: create a direct-to-consumer genetics company where customers could order a DNA kit online, mail back a saliva sample, and receive genetic information without needing a physician or hospital.

No referral. No insurance approval. No clinic visit.

Just genetics delivered directly to your doorstep.

The company name itself carried the entire mission: 23andMe — twenty-three chromosome pairs, and one unique individual.

The Science: Turning DNA Into Consumer Technology

Here's where the scientific architecture becomes interesting.

Many people assume that 23andMe performed complete genome sequencing. In reality, their primary technology relied on SNP genotyping chips.

SNPs, or single nucleotide polymorphisms, are tiny genetic variations spread across the genome. Think of the human genome as a three-billion-letter instruction manual. Humans share approximately 99.9% of that manual, but the remaining 0.1% contains remarkable biological information.

That small percentage can reveal ancestry patterns, disease susceptibility, differences in drug metabolism, inherited traits, and familial relationships.

Instead of reading every letter in the genome, 23andMe focused on strategically selected locations across DNA. This dramatically lowered costs.

At the time, sequencing an entire genome could cost millions of dollars. Genotyping reduced that cost to something consumers could actually afford.

And once science becomes scalable, it becomes business.

Rise to Fame: Oprah, Silicon Valley, and Mainstream Genetics

23andMe officially launched in 2007.

Initially, testing kits cost nearly $1,000. Today that sounds extraordinary, but early adopters were fascinated by the concept.

Silicon Valley loved it. Investors loved it. The media loved it.

Then came high-profile attention. Oprah discussed the product. Google invested in the company. Anne Wojcicki's connections to Silicon Valley also generated substantial visibility.

Eventually prices dropped from hundreds of dollars toward the sub-$100 range.

That changed everything.

Millions of people started asking themselves a very simple question: Why not?

Some wanted ancestry information. Others wanted health reports. Some simply wanted to satisfy curiosity.

Curiosity turned into an extremely powerful business model.

By the late 2010s, millions of customers had submitted saliva samples, creating one of the largest consumer genetic databases in history.

But beneath the DNA kits sat a much bigger strategy.

The Hidden Business Model: The Database Nobody Saw Coming

Most consumers believed they were buying a DNA test.

23andMe believed they were building a research engine.

Every consenting customer generated multiple layers of information: genetic data, survey responses, health histories, lifestyle information, and phenotypic characteristics.

Imagine millions of genomes connected with real-world health outcomes.

Traditional research studies often involve thousands of patients.

23andMe eventually had access to millions.

And pharmaceutical companies began paying attention.

The Big Pharma Era: The GSK Partnership

In 2018, 23andMe signed a major partnership with GSK.

The collaboration was initially valued at roughly $300 million and focused on one thing: improving drug discovery.

The reasoning was straightforward. If large-scale human genetics could identify genetic variants associated with disease, researchers could potentially identify stronger therapeutic targets.

Nature itself becomes a massive experiment.

Scientists can ask questions such as: Why do some people naturally avoid disease? Why are certain individuals protected? Which genes increase or decrease risk?

Historically, most drugs entering development fail.

Human genetic evidence may increase the probability of success.

Suddenly, 23andMe wasn't simply selling ancestry reports.

They were becoming a genetics platform for pharmaceutical research.

IPO Story: SPAC Euphoria and Public Market Reality

In 2021, 23andMe entered public markets through a SPAC merger.

At the time, SPACs dominated financial headlines. Investors were aggressively pursuing companies promising disruption and rapid growth.

23andMe achieved a valuation exceeding $3 billion.

People envisioned personalized medicine, predictive healthcare, AI-driven biology, and consumer genomics becoming routine.

But reality arrived quickly.

DNA testing kits are not naturally recurring purchases. Most customers buy one kit, learn about their ancestry, and rarely need another.

Drug development takes years.

Research monetization takes years.

Biology simply moves slower than software.

And public markets rarely enjoy waiting.

Criticism and Controversies: The Privacy Question

One of the largest questions surrounding 23andMe became surprisingly simple:

What exactly happens to your DNA?

Unlike passwords or email addresses, genetic information cannot be replaced. You can reset a password. You cannot reset your genome.

Concerns around genetic privacy continued to grow, and those concerns intensified after security incidents involving customer data.

The debate expanded beyond cybersecurity and entered philosophical territory.

Because your DNA doesn't belong entirely to you.

Your genome also carries information about parents, siblings, children, and relatives who never consented to share it.

23andMe ultimately became a case study not only in genomics, but also in ethics.

Fall of 23andme

The downfall of 23andMe stands as a cautionary tale of a company that captured the public imagination but failed to build a sustainable economic "System" beyond its initial novelty. After pioneering direct-to-consumer genetic testing, the company hit a massive growth ceiling; the "viral" phase of DNA kit sales waned once the early adopters were accounted for, and the company struggled to transition into a recurring revenue model. Furthermore, a catastrophic data breach in 2023 destroyed the core currency of the business—consumer trust—and decimated its valuation. By 2024, the company was hemorrhaging cash, its stock price had plummeted into penny-stock territory, and its pivot into drug discovery proved to be a capital-intensive "bridge to nowhere" that drained the remaining reserves faster than they could produce a clinical candidate.

When the company inevitably slid toward Chapter 11 bankruptcy in early 2025, it became a prime target for industry giants looking to acquire its unique asset: the largest database of human genotypic and phenotypic information on earth. Regeneron, led by its long-standing focus on deep human genetics, saw this as the ultimate R&D accelerator. In May 2025, Regeneron emerged as the primary bidder with a $256 million offer, intending to merge this "Big Data" with their proprietary Velocisuite platforms to speed up target identification. The acquisition was framed not as a rescue of 23andMe’s consumer business, but as a strategic extraction of its research engine and biobank—a move that would have theoretically given Regeneron an unmatched edge in drug discovery.

However, the deal collapsed during a dramatic auction in mid-2025. In a surprise maneuver, 23andMe’s former CEO, Anne Wojcicki, launched a competing bid through her nonprofit, the TTAM Research Institute, with an offer of $305 million. Regeneron, maintaining its disciplined approach to capital allocation and wary of entering a bidding war for a distressed, high-liability asset, chose to withdraw its offer. The board ultimately accepted the TTAM bid, and as of May 2026, 23andMe is operating under a restructured, private ownership model led by Wojcicki. The company is currently attempting to pivot back to its roots, focusing on core genetics while drastically shrinking its drug discovery footprint, while Regeneron has moved on, continuing to rely on its internal R&D platforms to drive its oncology and cardiovascular pipelines.

Lessons From 23andMe

The first lesson is that data can become more valuable than products themselves. The saliva kits generated revenue, but the database generated strategic value. The kits were the front door; the data ecosystem became the long-term destination.

The second lesson is that biology rarely follows software timelines. Silicon Valley frequently expects rapid growth and immediate scaling, while genetics and drug development often operate across decades.

The third lesson is that consumer trust becomes infrastructure. Customers were not simply buying a product; they were entrusting a company with biological identity. Once that trust weakens, rebuilding it becomes difficult.

Finally, personalized medicine requires much more than genetics alone. Genes matter enormously, but they represent only one part of a much larger biological story involving environment, behavior, and lifestyle.

What's Next for 23andMe?

The newest chapter appears increasingly focused on integrating genetic information with medical records, AI-driven health insights, and deeper ancestry analysis.

The larger industry question extends far beyond a single company:

Will genomics eventually become a routine part of healthcare? Will every patient one day have a genetic profile integrated into medical records? And perhaps most importantly, who controls those systems?

Because the future of genetics may not simply be about understanding where you came from.

It may be about predicting where you're going.

Outro: Biology as Identity

23andMe's story is complicated.

It's a story about ambition, about democratizing science, about consumer technology colliding with biology, and about what happens when data becomes more valuable than anyone initially expected.

They placed genetics into millions of homes and changed how ordinary people think about DNA.

Whether their long-term legacy becomes ancestry, therapeutics, or data infrastructure remains uncertain.

But one thing is undeniable:

They made genomics personal.

And remember: your genome may be written in billions of letters, but sometimes a few thousand data points are enough to change an entire industry.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References 

1. https://www.23andme.com/
2. www.wikipedia.org
3. https://www.fiercebiotech.com/ 
4. https://finance.yahoo.com/ 
5. https://endpoints.news/